Answers are grounded in this paper and cite their sources.
In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: